Apollomics Reports Top-line Data from P-III Bridging Study of Uproleselan in Chinese Patients with R/R Acute Myeloid Leukemia (AML)
Shots:
- Apollomics has reported topline data from the P-III bridging study assessing safety & efficacy of uproleselan + CT (n=69) vs CT alone (n=71) in r/r AML patients (N=140)
- Study did not achieve favorable benefits with the combination vs CT alone, showing mOS of 9.3mos. vs 14.3mos. The company will highlight full data at upcoming conference
- Safety was well-tolerated and similar in both the arms, showing 43% vs 39% SAE incidence, with most common of them being decreased platelet count, infectious pneumonia & sepsis. The company is wrapping up the program
Ref: Apollomics | Image: Apollomics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
